演題詳細
Oral
アルツハイマー病、他の認知症、老化 4
Alzheimer's Disease, Other Dementia, Aging 4
開催日 | 2014/9/12 |
---|---|
時間 | 16:00 - 17:00 |
会場 | Room I(311+312) |
Chairperson(s) | 古川 勝敏 / Katsutoshi Furukawa (東北大学加齢医学研究所老年医学分野 / Department of Geriatrics and Gerontology, Division of Brain Sciences, Institute of Development Aging and Cancer, Tohoku University, Jap) 遠山 育夫 / Ikuo Tooyama (滋賀医科大学分子神経科学研究センター / Molecular Neuroscience Research Center, Shiga University of Medical Science, Japan) |
[18F]THK-5117 PETによるアルツハイマー病のタウ病理像の生体画像化
In vivo imaging of tau pathology in Alzheimer’s disease using [18F]THK-5117 PET
- O2-I-4-2
- 原田 龍一 / Ryuichi Harada:1,2 岡村 信行 / Nobuyuki Okamura:2 古本 祥三 / Shozo Furumoto:3,5 古川 勝敏 / Katsutoshi Furukawa:4 石木 愛子 / Aiko Ishiki:4 冨田 尚希 / Naoki Tomita:4 多胡 哲郎 / Tetsuro Tago:5 岩田 錬 / Ren Iwata:5 田代 学 / Manabu Tashiro:5 荒井 啓行 / Hiroyuki Arai:4 谷内 一彦 / Kazuhiko Yanai:2 工藤 幸司 / Yukitsuka Kudo:1
- 1:東北大学加齢医学研究所 / Divi Neuro-imaging, Institute of Development, Aging and Cancer, Tohoku Univ, Sendai, Japan 2:東北大学医学系研究科機能薬理学分野 / Dept Pharmacol, Tohoku Univ Grad School of Med, Sendai, Japan 3:東北大学学際科学フロンティア研究所 / Frontier Research Institute for Interdisciplinary Science, Tohoku Univ, Sendai, Japan 4:東北大学加齢医学研究所老年医学研究分野 / Dept Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku Univ, Sendai, Japan 5:東北大学サイクロトロンRIセンター / CYRIC, Tohoku Univ, Sendai, Japan
Neurofibrillary pathology containing microtubule-associated protein tau is one of the neuropathological hallmarks in Alzheimer's disease (AD). Non-invasive detection of neurofibrillary tangles in living subjects would provide not only clinical advantages such as diagnosis and treatment but also better understanding of pathophysiology in AD. We have developed arylquinoline derivatives as potential candidates for tau-selective PET tracers. The aim of study was to validate the clinical usefulness of [18F]THK-5117 as a tau-selective PET tracer. Methods: In vitro binding assays and autoradiography of THK-5117 were conducted using human brain tissues to validate the binding selectivity to neurofibrillary pathology, compared with amyloid PET tracer PiB. Clinical PET studies with [18F]THK-5117 and [11C]PiB were conducted in fourteen participants including eight Alzheimer's patients and six healthy controls. Results: Selective binding of THK-5117 to neurofibrillary pathology was observed in post-mortem brain tissues from AD. In human PET study, patients with AD had increased [18F]THK-5117 retention compared to healthy subjects. Regional distribution of [18F]THK-5117 was similar to the pattern of neurofibrillary pathology typically seen in postmortem analyses of patients with AD, which was obviously different from that of [11C]PiB. In addition, [18F]THK-5117 uptake in the mesial temporal cortex was correlated with hippocampal volume in AD patients. Conclusion: [18F]THK-5117 selectively binds to neurofibrillary pathology in AD patients, providing regional quantitative information on tau pathology in living subjects. In combination with amyloid PET imaging, non-invasive imaging of neurofibrillary pathology may shed light on the true nature of AD-related pathophysiology in humans.